ALNYLAM PHARMACEUTICALS, INC.

Form 4

December 04, 2007

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB 3235-0287 Number:

January 31, Expires: 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

| 1. Name and Address of Reporting Person * SCHIMMEL PAUL | | | 2. Issuer Name and Ticker or Trading Symbol | 5. Relationship of Reporting Person(s) to Issuer | | |
|---|---------|----------|--|---|--|--|
| | | | ALNYLAM PHARMACEUTICALS, INC. | (Check all applicable) | | |
| | | | [ALNY] | X Director 10% Owner | | |
| (Last) | (First) | (Middle) | 3. Date of Earliest Transaction | Officer (give title Other (specify below) | | |
| 300 THIRD STREET | | | (Month/Day/Year) 11/30/2007 | | | |
| (Street) | | | 4. If Amendment, Date Original | 6. Individual or Joint/Group Filing(Check | | |
| CAMPRIDGE MA 02142 | | | Filed(Month/Day/Year) | Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting | | |

CAMBRIDGE, MA 02142

(State)

(Zip)

(City)

| Table I - Non-Derivative | Contract A softimed | Disposed of on I | Danafiaially Owned |
|--------------------------|---------------------|------------------|--------------------|
| | | | |

Person

| • | | - Iai | 16 1 - 14011- | Derivative | Secui | rues Acqui | ieu, Disposeu oi, | of Deficition | y Owneu |
|--------------------------------------|---|---|--|--|---------|------------|--|--|---|
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transactic Code (Instr. 8) | 4. Securit ord Dispos (Instr. 3, | ed of (| ` ′ | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Common Stock | 11/30/2007 | | M | 10,000 | A | \$ 7.08 | 248,088 | D | |
| Common Stock | 11/30/2007 | | M | 10,000 | A | \$ 14.74 | 258,088 | D | |
| Common Stock | 11/30/2007 | | S | 10,000 | D | \$ 33.5 | 248,088 | D | |
| Common Stock | 11/30/2007 | | S | 1,619 | D | \$ 33.5 | 246,469 | D | |
| Common Stock | 11/30/2007 | | S | 300 | D | \$ 33.51 | 246,169 | D | |

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

| Common Stock | 11/30/2007 | S | 500 | D | \$ 33.52 | 245,669 | D | |
|-----------------|------------|---|-------|---|---------------|---------|---|----------|
| Common Stock | 11/30/2007 | S | 1,800 | D | \$ 33.6 | 243,869 | D | |
| Common Stock | 11/30/2007 | S | 100 | D | \$ 34 | 243,769 | D | |
| Common Stock | 11/30/2007 | S | 2,664 | D | \$ 34.13 | 241,105 | D | |
| Common Stock | 11/30/2007 | S | 536 | D | \$ 34.1301 | 240,569 | D | |
| Common Stock | 11/30/2007 | S | 300 | D | \$ 34.139 | 240,269 | D | |
| Common Stock | 11/30/2007 | S | 500 | D | \$ 34.16 | 239,769 | D | |
| Common Stock | 11/30/2007 | S | 1,681 | D | \$ 34.2 | 238,088 | D | |
| Common Stock | 11/30/2007 | S | 8,365 | D | \$ 32.9 | 90,020 | I | by Trust |
| Common Stock | 11/30/2007 | S | 300 | D | \$ 32.91 | 89,720 | I | by Trust |
| Common Stock | 11/30/2007 | S | 200 | D | \$ 32.92 | 89,520 | I | by Trust |
| Common Stock | 11/30/2007 | S | 100 | D | \$ 32.95 | 89,420 | I | by Trust |
| Common Stock | 11/30/2007 | S | 200 | D | \$ 32.96 | 89,220 | I | by Trust |
| Common Stock | 11/30/2007 | S | 1,500 | D | \$ 33.05 | 87,720 | I | by Trust |
| Common Stock | 11/30/2007 | S | 800 | D | \$ 33.07 | 86,920 | I | by Trust |
| Common Stock | 11/30/2007 | S | 100 | D | \$ 33.08 | 86,820 | I | by Trust |
| Common Stock | 11/30/2007 | S | 2,000 | D | \$ 33.25 | 84,820 | I | by Trust |
| Common Stock | 11/30/2007 | S | 2,500 | D | \$ 33.29 | 82,320 | I | by Trust |
| Common Stock | 11/30/2007 | S | 500 | D | \$ 33.3 | 81,820 | I | by Trust |
| Common Stock | 11/30/2007 | S | 657 | D | \$ 33.35 | 81,163 | I | by Trust |
| | 12/03/2007 | S | 2,150 | D | \$ 32.3 | 79,013 | I | by Trust |

| Common Stock | | | | | | | | |
|-----------------|------------|---|-------|---|----------|--------|---|----------|
| Common Stock | 12/03/2007 | S | 400 | D | \$ 32.35 | 78,613 | I | by Trust |
| Common Stock | 12/03/2007 | S | 5,836 | D | \$ 32.5 | 72,777 | I | by Trust |
| Common Stock | 12/03/2007 | S | 1,800 | D | \$ 33 | 70,977 | I | by Trust |
| Common Stock | 12/03/2007 | S | 1,400 | D | \$ 33.01 | 69,577 | I | by Trust |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercis Expiration Dat (Month/Day/Y | ite | 7. Title and Underlying S (Instr. 3 and | Secur |
|---|---|---|---|---|---|--------------------|---|------------------------|
| | | | Code V | (A) (D) | Date Exercisable | Expiration Date | Title | Am or Nu of S |
| Non-Qualified Stock Option (right to buy) | \$ 7.08 | 11/30/2007 | M | 10,000 | 06/08/2006 | 06/08/2015 | Common Stock | 10 |
| Non-Qualified Stock Option (right to buy) | \$ 14.74 | 11/30/2007 | M | 10,000 | 06/01/2007 | 06/01/2016 | Common Stock | 10 |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | | |
|--------------------------------|---------------|-----------|---------|-------|--|--|--|
| r g | Director | 10% Owner | Officer | Other | | | |
| SCHIMMEL PAUL | | | | | | | |
| 300 THIRD STREET | X | | | | | | |
| CAMBRIDGE, MA 02142 | | | | | | | |

Reporting Owners 3

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

Signatures

By: /s/ Patricia L. Allen, Attorney-in-Fact For: Paul R Schimmel

12/04/2007

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The indirectly held shares listed on this Form 4 are held by Paul Schimmel as Trustee of the Paul Schimmel Prototype PSP.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 4